Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt repayments

Daily Values

Growth Metrics

Medpace Holdings (MEDP) Short-Term Debt issuances (2017 - 2023)

Medpace Holdings filings provide 3 years of Short-Term Debt issuances readings, the most recent being $15.0 million for Q2 2023.

On a quarterly basis, Short-Term Debt issuances fell 93.99% to $15.0 million in Q2 2023 year-over-year; TTM through Mar 2024 was $15.0 million, a 95.89% decrease, with the full-year FY2023 number at $105.0 million, down 67.61% from a year prior.
Short-Term Debt issuances hit $15.0 million in Q2 2023 for Medpace Holdings, down from $90.0 million in the prior quarter.
In the past five years, Short-Term Debt issuances ranged from a high of $249.7 million in Q2 2022 to a low of $15.0 million in Q2 2023.